Topical histone deacetylase 1 inhibitor Entinostat ameliorates psoriasiform dermatitis through suppression of IL-17A response

Biologics against IL-17A, IL-23 and TNF- α achieve a great success in treating psoriasis. However, the majority of patients still have some residual lesions left and require combination therapy to reach complete clearance. Topical medicine is an optional choice but only has limited categories. Besides, drug resistance is very often. Thus, topical medicine targeting new signaling pathway is still in an urgent need in the biologics era. ObjectiveTo investigate the role of topical Entinostat, a selective inhibitor of histone deacetylases 1 (HDAC1) has been tested in clinic trials to treat solid tumors and hematological malignancies, in psoriasis therapy.
Source: Journal of Dermatological Science - Category: Dermatology Authors: Source Type: research